Overview
This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.
Eligibility
Inclusion Criteria:
- Adults ≥18 years of age
- Clinical diagnosis of T1D
- GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week
- Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study
- Willing and able to provide informed consent
Exclusion Criteria:
- No exclusion criteria other than those not meeting inclusion criteria above


